


SCARD Pool report for 01-01-2014 to 31-12-2014

| | | | |
|---------------------|-----------------------------|---------|---------|
| Participants | Doctors | 258 | |
| | Patients | 44,847 | |
| Specimens | New lesions | 86,896 | 84.98% |
| | Previously biopsied lesions | 15,359 | 15.02% |
| | Total lesions | 102,255 | 100.00% |

Breakdown of new versus previously biopsied specimens


| | |
|--|--------|
| Percentage of new lesions tested which were malignant | 61.49% |
| Percentage of Definitively excised lesions that were malignant | 78.60% |
| Lesions tested to find one melanoma (NNT) | 5.14 |
| Percentage of lesions tested for NMSC which were NMSC | 73.07% |
| Ratio of New BCCs : New Melanomas | 11:1 |

Accuracy
Diagnostic sensitivity

| | |
|-----------|------------------|
| Melanomas | 70.95% of 2,406 |
| All NMSC | 95.03% of 50,261 |
| BCCs | 89.95% of 26,027 |
| SCCs | 82.39% of 23,976 |

Positive predictive value



| | |
|-----------|------------------|
| Melanomas | 44.02% of 3,878 |
| All NMSC | 79.36% of 60,186 |
| BCCs | 38.90% of 60,186 |
| SCCs | 64.60% of 30,580 |

Adequacy
Percentage of definitively managed malignant cases where surgical margins were adequate

| | |
|---------------------------|------------------|
| BCC | 85.73% of 17,742 |
| IEC/Bowens disease | 88.17% of 8,520 |
| SCC | 89.95% of 5,899 |
| Keratoacanthoma | 93.89% of 868 |
| Melanoma - in situ | 75.92% of 1,603 |
| Melanoma - invasive | 74.95% of 487 |
| Melanoma - invasive > 1mm | 49.25% of 67 |
| Other malignant | 77.61% of 67 |

Lesion Breakdown
Histological Diagnosis

| | | |
|-----------------------------|--------|--------|
| BCC (unspecified type) | 0 | 0% |
| BCC - Superficial | 8,850 | 10.18% |
| BCC - Nodular/Solid | 12,513 | 14.39% |
| BCC - Aggressive | 4,664 | 5.36% |
| IEC/Bowens disease | 14,644 | 16.84% |
| SCC | 8,081 | 9.29% |
| Keratoacanthoma | 1,251 | 1.44% |
| Pinkus Fibroepithelioma | 12 | 0.01% |
| Merkel cell tumour | 5 | 0.01% |
| Other malignant | 100 | 0.12% |
| NMSC Metastasis | 6 | 0.01% |
| Melanoma - in situ | 1,681 | 1.93% |
| Melanoma - invasive | 563 | 0.65% |
| Melanoma - invasive > 1mm | 133 | 0.15% |
| Melanoma - metastasis | 29 | 0.03% |
| MELTUMP | 135 | 0.16% |
| Naevus - other | 4,616 | 5.31% |
| Naevus - dysplastic/Clark | 3,235 | 3.72% |
| Naevus - blue | 278 | 0.32% |
| Naevus - Spitz/Reed | 139 | 0.16% |
| Naevus - Compound | 0 | 0% |
| Solar keratosis | 8,844 | 10.17% |
| Solar lentigo | 1,265 | 1.45% |
| Seborrhoeic keratosis | 4,623 | 5.32% |
| Lentigo Simplex | 1 | 0.00% |
| Lichenoid keratosis (LPLK) | 1,643 | 1.89% |
| Dermatofibroma | 675 | 0.78% |
| Sebaceous gland hyperplasia | 175 | 0.20% |
| Benign cyst | 1,157 | 1.33% |
| Other benign | 6,098 | 7.01% |
| Histology Pending | 53 | 0.06% |



Procedures
Definitive Surgical Management used to exclude melanoma

| | | |
|-----------------------|-------|--------|
| Ellipse | 1,991 | 91.50% |
| Flap | 51 | 2.34% |
| Graft - SSG | 6 | 0.28% |
| Graft - FTSG | 9 | 0.41% |
| No Closure | 4 | 0.18% |
| Shave/Saucerisation | 40 | 1.84% |
| Curettage & Cautery | 19 | 0.87% |
| Liquid N2 freeze/thaw | 3 | 0.14% |
| PDT | 0 | 0% |
| Imiquimod | 1 | 0.05% |
| 5 FU cream | 0 | 0% |
| GP referral | 10 | 0.46% |
| Specialist referral | 36 | 1.65% |
| Other | 3 | 0.14% |

Biopsy used to exclude melanoma

| | | |
|-----------------|-------|--------|
| Punch - sample | 633 | 6.14% |
| Shave - sample | 1,121 | 10.87% |
| Incisional | 105 | 1.02% |
| Punch - removal | 2,063 | 20.00% |
| Shave - removal | 3,304 | 32.04% |
| Excisional | 3,026 | 29.34% |
| Curettage | 54 | 0.52% |
| Other | 4 | 0.04% |

Breakdown of definitive management procedures for malignant conditions

| | | |
|-----------------------|--------|--------|
| Ellipse | 32,120 | 66.13% |
| Flap | 4,203 | 8.65% |
| Graft - SSG | 255 | 0.52% |
| Graft - FTSG | 746 | 1.54% |
| No Closure | 195 | 0.40% |
| Shave/Saucerisation | 460 | 0.95% |
| Curettage & Cautery | 6,323 | 13.02% |
| Liquid N2 freeze/thaw | 1,003 | 2.06% |
| PDT | 72 | 0.15% |
| Imiquimod | 601 | 1.24% |
| 5 FU cream | 788 | 1.62% |
| GP referral | 84 | 0.17% |
| Specialist referral | 1,110 | 2.29% |
| Other | 177 | 0.36% |

Breakdown of definitive management procedures for benign conditions

| | | |
|-----------------------|-------|--------|
| Ellipse | 4,380 | 71.52% |
| Flap | 94 | 1.53% |
| Graft - SSG | 1 | 0.02% |
| Graft - FTSG | 6 | 0.10% |
| No Closure | 8 | 0.13% |
| Shave/Saucerisation | 553 | 9.03% |
| Liquid N2 freeze/thaw | 349 | 5.70% |
| 5 FU cream | 65 | 1.06% |
| GP referral | 15 | 0.24% |
| Specialist referral | 46 | 0.75% |
| Other | 56 | 0.91% |

Procedures (continued)
Percentage of procedures/closures that were complex

| | |
|--|------------------|
| Complex Closures | 10.94% of 51,247 |
| Complex Closures (inc Curettage & Cautery) | 9.65% of 58,087 |

Locations
Breakdown of melanomas by location and percentage melanomas of total lesions at that location

| | | |
|---------------|-----|-----------------|
| Nose | 35 | 0.66% of 5,319 |
| Lip | 5 | 0.35% of 1,444 |
| Ear | 51 | 1.41% of 3,610 |
| Eyelid | 8 | 0.98% of 813 |
| Other face | 272 | 1.77% of 15,406 |
| Scalp | 56 | 1.95% of 2,872 |
| Neck | 114 | 2.72% of 4,186 |
| Shoulder | 173 | 4.34% of 3,987 |
| Chest | 108 | 2.12% of 5,100 |
| Abdomen | 63 | 5.83% of 1,080 |
| Genitalia | 2 | 1.98% of 101 |
| Back | 706 | 5.67% of 12,441 |
| Buttock | 6 | 2.58% of 233 |
| Arm | 229 | 4.66% of 4,917 |
| Forearm | 144 | 1.98% of 7,262 |
| Hand Dorsal | 4 | 0.11% of 3,581 |
| Hand Palmar | 0 | 0% of 25 |
| Finger Dorsal | 0 | 0% of 994 |
| Finger Nail | 1 | 8.33% of 12 |
| Finger Palmar | 0 | 0% of 14 |
| Thigh | 135 | 5.27% of 2,561 |
| Leg | 271 | 2.72% of 9,952 |
| Foot Dorsal | 18 | 2.46% of 733 |
| Foot Plantar | 1 | 1.08% of 93 |
| Toe Dorsal | 4 | 3.25% of 123 |
| Toe Nail | 0 | 0% of 18 |
| Toe Plantar | 0 | 0% of 19 |
| Palm Or Sole | 0 | 0% of 0 |

